A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Public ClinicalTrials.gov record NCT05968326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Study identification
- NCT ID
- NCT05968326
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 260 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 18, 2023 (Actual)
- Primary completion
- Jan 1, 2031 (Estimated)
- Completion
- Jan 1, 2031 (Estimated)
- Last update posted
- Sep 9, 2026
2023 – 2031
United States locations
- U.S. sites
- 30
- U.S. states
- 14
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| USC Norris Cancer Center | Newport Beach | California | 92663 | — |
| University of California, San Francisco (UCSF) | San Francisco | California | 94158-2350 | — |
| University of California Los Angeles | Santa Monica | California | 90404 | — |
| St. Francis Hospital and Medical Center | Hartford | Connecticut | 06105 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Smilow Cancer Hospital Care Center at Trumbull | Trumbull | Connecticut | 06611 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| Indiana University Health Melvin & Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Kentucky Medical Center | Lexington | Kentucky | 40536 | — |
| Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center | Boston | Massachusetts | 02114-2621 | — |
| Boston Medical Center (BMC) - Cancer Care Center | Boston | Massachusetts | 02118 | — |
| Henry Ford Health System | Detroit | Michigan | 48202-2610 | — |
| University of Nebraska | Omaha | Nebraska | 68198-5300 | — |
| Memorial Sloan Kettering Cancer Center Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| Memorial Sloan Kettering Cancer Center | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering Cancer Center at Bergen | Montvale | New Jersey | 07645 | — |
| Memorial Sloan Kettering Cancer Center - Commack | Commack | New York | 11725 | — |
| Memorial Sloan Kettering Cancer Center at Westchester | Harrison | New York | 10604 | — |
| Northwell Health | Lake Success | New York | 11042 | — |
| Mount SInai Medical Center | New York | New York | 10029 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| MEETH-LHH Northwell Health Cancer Clinical Trials Office at MEETH-LHH | New York | New York | 10065-7471 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center at Nassau | Uniondale | New York | 11553 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710-4000 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45219 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Miriam Hospital | Providence | Rhode Island | 02906 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05968326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05968326 live on ClinicalTrials.gov.